Literature DB >> 17229341

Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.

Jatin J Shah1, Ruby Meredith, Sui Shen, Burt Nabors, Albert Lobuglio, Michael Yester, Andres Forero.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma arising within and confined to the central nervous system and, unlike other primary brain tumors, is very responsive to treatment. Aggressive management can lead to prolonged remissions or cures. However, the prognosis at relapse is generally poor with limited therapeutic options; clearly, new strategies are needed for these patients. Radioimmunotherapy has a growing role in the management of systemic non-Hodgkin lymphoma but has not been evaluated in PCNSL. We report here the first patient with PCNSL treated with radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17229341

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  1 in total

1.  First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.

Authors:  Sofiane Maza; Philipp Kiewe; Dieter L Munz; Agnieszka Korfel; Bernd Hamm; Kristoph Jahnke; Eckhard Thiel
Journal:  Neuro Oncol       Date:  2008-12-05       Impact factor: 12.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.